Last reviewed · How we verify
Orelabrutinib and R-CHOP
Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the activity of BTK, a protein involved in the activation of B cells.
Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the activity of BTK, a protein involved in the activation of B cells. Used for Non-Hodgkin lymphoma.
At a glance
| Generic name | Orelabrutinib and R-CHOP |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting BTK, orelabrutinib prevents the activation of B cells, which are a type of immune cell that plays a key role in the development of certain types of cancer. This mechanism of action is particularly effective in treating non-Hodgkin lymphoma, a type of blood cancer. Orelabrutinib has been shown to be effective in combination with R-CHOP, a chemotherapy regimen that is commonly used to treat non-Hodgkin lymphoma.
Approved indications
- Non-Hodgkin lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (PHASE2)
- Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients (PHASE2)
- CR-CHOP+X in Previously Untreated DEL (PHASE2)
- Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI (PHASE2)
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (PHASE3)
- An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma (PHASE2)
- Genotype-guided Treatment in DLBCL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Orelabrutinib and R-CHOP CI brief — competitive landscape report
- Orelabrutinib and R-CHOP updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI